Soligenix Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on rare diseases, has announced the closing of a $7.5 million public offering. The offering included the sale of 5,555,560 shares of common stock (or equivalents) and warrants to purchase an equal number of shares at a combined price of $1.35 per share and warrant. The warrants are immediately exercisable at $1.35 per share and will expire five years from the date of issuance. The company also amended certain outstanding warrants to match the new exercise price and expiration date. Soligenix plans to use the net proceeds to support research and development, commercialization activities, working capital, and general corporate purposes. This capital raise extends the company's cash runway through the end of 2026, funding multiple expected key inflection points. A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction.